Glaukos Corporation (NYSE:GKOS) CEO Thomas William Burns sold 73,788 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $41.36, for a total value of $3,051,871.68. The sale was disclosed in a filing with the SEC, which is available through this link.

Thomas William Burns also recently made the following trade(s):

  • On Tuesday, September 5th, Thomas William Burns sold 1,212 shares of Glaukos Corporation stock. The shares were sold at an average price of $41.25, for a total value of $49,995.00.

Shares of Glaukos Corporation (GKOS) traded up 1.33% during mid-day trading on Friday, hitting $42.00. The stock had a trading volume of 559,451 shares. The stock’s 50-day moving average is $38.45 and its 200-day moving average is $42.55. The firm’s market capitalization is $1.45 billion. Glaukos Corporation has a 1-year low of $28.72 and a 1-year high of $52.49.

ILLEGAL ACTIVITY WARNING: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/08/glaukos-corporation-gkos-ceo-thomas-william-burns-sells-73788-shares.html.

Institutional investors and hedge funds have recently modified their holdings of the company. Great West Life Assurance Co. Can bought a new position in shares of Glaukos Corporation during the first quarter worth about $102,000. Ameritas Investment Partners Inc. raised its position in shares of Glaukos Corporation by 93.1% during the second quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after acquiring an additional 1,212 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Glaukos Corporation by 740.6% during the second quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock worth $147,000 after acquiring an additional 3,118 shares during the last quarter. Prudential Financial Inc. bought a new position in shares of Glaukos Corporation during the first quarter worth about $204,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Glaukos Corporation during the second quarter worth about $262,000.

GKOS has been the subject of a number of recent analyst reports. Zacks Investment Research raised Glaukos Corporation from a “hold” rating to a “strong-buy” rating and set a $48.00 price target for the company in a research note on Tuesday, July 4th. BidaskClub cut Glaukos Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $56.00 price target on shares of Glaukos Corporation in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $52.33.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Insider Buying and Selling by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.